Tennessee is currently home to 1929 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.
NCT05035212
Recruiting
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * The duration of the study for each participant will be up to approximately 24 months. * The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa. Substudy A: This s... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/19/2024
Locations: Alliance for Multispecialty Research, LLC, Knoxville, Tennessee
Conditions: Lower Respiratory Tract Illness
Register for Updates
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811
Recruiting
The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: SCRI - Tennessee Oncology, Nashville, Tennessee
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT04814108
Recruiting
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: Ascension St. Thomas Midtown Hospital, Nashville, Tennessee
Conditions: Uterine Serous Carcinoma
Register for Updates
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT05919108
Recruiting
This phase II trial tests how well neratinib prior to the primary treatment (neoadjuvant) works in treating patients with stage I-III HER2 mutated lobular breast cancers. Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving neratinib in addition to normal therapy may work better in treating cancer than the endocrine therapy patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Anatomic Stage I Breast Cancer, Anatomic Stage II Breast Cancer, Anatomic Stage III Breast Cancer, Invasive Breast Lobular Carcinoma
Register for Updates
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
NCT03808922
Recruiting
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Gender:
ALL
Ages:
All
Trial Updated:
11/18/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
NCT02854033
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
11/18/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Register for Updates
Genetic Epidemiology of Rotator Cuff Tears: the CuffGEN Study
NCT04831164
Recruiting
Rotator cuff tear is one of the most common reasons to seek musculoskeletal care, and cuff repair is one of the fastest growing ambulatory surgery procedures. However, the etiology of cuff tears, reasons for variability treatment success, and causes of FI are poorly understood. A large-scale genome-wide association studies (GWAS) using imaging-verified rotator cuff tear cases and controls can address limitations in rigor of prior research and assess the genetic basis of FI and functional outcome... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
11/17/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Rotator Cuff Tears
Register for Updates
The ADAPT Trial: Adapting Evidence-Based Obesity Interventions in Community Settings
NCT06546696
Recruiting
Evidence-based obesity treatment is inaccessible to most children in the United States. This lack of access is a source of health inequity, whereby children from rural and minority communities, who have the highest rates of childhood obesity, are also the least likely to receive an evidence-based intervention. Developing strategies to improve access to evidence-based obesity interventions could reduce health disparities by improving reach to these underserved communities. The premise of this stu... Read More
Gender:
ALL
Ages:
Between 6 years and 12 years
Trial Updated:
11/15/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Childhood Obesity
Register for Updates
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
NCT04794699
Recruiting
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with other anticancer agents including taxanes (docetaxel, paclitaxel), or sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/15/2024
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Solid Tumor
Register for Updates
Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
NCT05860296
Recruiting
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the stud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Nashville Oncology Associates, Nashville, Tennessee
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Register for Updates
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
NCT04770337
Recruiting
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse even... Read More
Gender:
ALL
Ages:
9 years and above
Trial Updated:
11/14/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Register for Updates
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
NCT06034275
Recruiting
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: TriStar Bone Marrow Transplant, Nashville, Tennessee
Conditions: Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome
Register for Updates